Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

295.18 +0.65 (+0.22%)
Streaming Delayed Price Updated: 3:22 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
47 48 Next >
As Its Stock Gets Set For Upgrade, Boan Biotech Still Faces Two Big Risks
Key Takeaways: With two products now generating revenue, Boan Biotech will soon have the “B” marker for high-risk tickers removed from its stock symbol Boan faces stiff competition in its main area of... 
Via Benzinga
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Match, DraftKings, SVB, and Amgen and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Price Over Earnings Overview: Amgen
Via Benzinga
Where Amgen Stands With Analysts
Via Benzinga
1 Dividend Growth Stock to Buy Hand Over Fist
Investing in dividend stocks, particularly those that raise their payouts regularly, can pay off massively in time. 
Via The Motley Fool
Amgen's Debt Overview
Via Benzinga
AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amgen Inc. (NASDAQ: AMGN)
From Bernstein Liebhard LLP
Via GlobeNewswire
7 Dividend Stocks to Buy That Are Backed by Strong Cash Flows
Cash is king and this article highlights seven dividend stocks with strong cash flows and an emphasis on free cash flow. 
Via InvestorPlace
Novo Nordisk Surges To Another Record As Obesity Drugs Drive Higher Outlook
Demand for Wegovy and Ozempic prompted Novo to raise its full-year outlook. 
Via Investor's Business Daily
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DraftKings, SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
A Look Into Amgen Inc's Price Over Earnings
Via Benzinga
Red-Hot Obesity-Drug Maker Novo Nordisk Soars To Record On A $725 Million Deal
Novo Nordisk is already a leader in obesity treatment with Saxenda and Wegovy. 
Via Investor's Business Daily
These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
AMGN SHAREHOLDER ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
From The Rosen Law Firm, P.A.
Via Business Wire
Weight Watchers Reshapes Itself with a Game-Changer Acquisition
Weight management meals and services provider WW International Inc. (NYSE: WW) spike over 25% as it closed its acquisition of telehealth weight loss platform 
Via MarketBeat
Lowey Dannenberg Notifies Amgen, Inc. (NASDAQ: AMGN) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Can You Still Buy the Dow Jones' Best-Performing April Stocks?
Each is benefiting from recent good news, but there's also a theme-based tailwind brewing that could last a while. 
Via The Motley Fool
Love Dividends? These 3 Stocks Are Smart Buys Right Now
With yields of 3.1%, 3.4%, and 14.3%, these stocks are hard to pass up right now. 
Via The Motley Fool
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up... 
Via Talk Markets
ROSEN, A LONGSTANDING LAW FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AMGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DraftKings, SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
From The Rosen Law Firm PA
Via GlobeNewswire
7 Very Undervalued Penny Stocks to Buy in April 2023
Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option. 
Via InvestorPlace
Amgen Inc. (NASDAQ: AMGN) Shareholder Alert: Lawsuit Alleges Misleading Statements
San Diego, CA -- (SBWIRE) -- 04/06/2023 -- An investor, who purchased shares of Amgen Inc. (NASDAQ: AMGN), filed a lawsuit over alleged violations of Federal Securities Laws by Amgen Inc. in connection... 
Via SBWire
Income Investors: These 2 Stocks Have Quadrupled Their Dividend Payouts Over the Past 10 Years
These two stocks have generated massive dividend growth for shareholders in the last decade. 
Via The Motley Fool
3 Must-Buy Dow Stocks for Your April Buy List
The range of Dow stocks to choose from is small, but there are plenty of great opportunities for investors to choose from. 
Via InvestorPlace
3 Dow Stocks With Above-Average Dividends Yields to Buy in April
Income-seeking investors are going to love the annual payout raises and yields of 2.9% or better that these legendary dividend payers offer right now. 
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, Signature, and Norfolk Southern and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AMGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Regulatory Compliance
Exposures Financial Legal Regulatory
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.